Chronic Wound Biofilm Model

Ganesh, Kasturi; Sinha, Mithun; Mathew-Steiner, Shomita S.; Das, Amitava; Roy, Sashwati; Sen, Chandan K.

doi:10.1089/wound.2014.0587

Cited by 69 publications

(96 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To discover new biofilm-eradicating agents, we have established an interdisciplinary research program involving syntheticm edicinal chemistry,m icrobiology and molecular biology.F romt hese efforts,w eh ave identified as eries of halogenatedp henazines( HPs) that potently eradicate bacterialb iofilms, and future work aims to translatet hese preliminaryf indings into ground-breaking clinical advances for the treatment of persistentb iofilm infections. periodontitis, [40] osteomyelitis, [39,40] skin/burn wounds, [42][43][44] implanted medicald evices (i.e.,h eart valve, [45] prosthetic joint [46,47] ), cystic fibrosis (chronic lung infections [39,40] ), catheterrelated infections [40,[48][49][50][51] (e.g.,u rinary catheters [40] central venous catheters, [50] cerebrospinalf luid shunts [51] )a nd caries (tooth decay [52] ).…”

Section: Introductionmentioning

confidence: 99%

Phenazine Antibiotic‐Inspired Discovery of Bacterial Biofilm‐Eradicating Agents

2019

View full text Add to dashboard Cite

Bacterial biofilms are surface‐attached communities of slow‐growing and non‐replicating persister cells that demonstrate high levels of antibiotic tolerance. Biofilms occur in nearly 80 % of infections and present unique challenges to our current arsenal of antibiotic therapies, all of which were initially discovered for their abilities to target rapidly dividing, free‐floating planktonic bacteria. Bacterial biofilms are credited as the underlying cause of chronic and recurring bacterial infections. Innovative approaches are required to identify new small molecules that operate through bacterial growth‐independent mechanisms to effectively eradicate biofilms. One source of inspiration comes from within the lungs of young cystic fibrosis (CF) patients, who often endure persistent Staphylococcus aureus infections. As these CF patients age, Pseudomonas aeruginosa co‐infects the lungs and utilizes phenazine antibiotics to eradicate the established S. aureus infection. Our group has taken a special interest in this microbial competition strategy and we are investigating the potential of phenazine antibiotic‐inspired compounds and synthetic analogues thereof to eradicate persistent bacterial biofilms. To discover new biofilm‐eradicating agents, we have established an interdisciplinary research program involving synthetic medicinal chemistry, microbiology and molecular biology. From these efforts, we have identified a series of halogenated phenazines (HPs) that potently eradicate bacterial biofilms, and future work aims to translate these preliminary findings into ground‐breaking clinical advances for the treatment of persistent biofilm infections.

show abstract

Section: Introductionmentioning

confidence: 99%

Phenazine Antibiotic‐Inspired Discovery of Bacterial Biofilm‐Eradicating Agents

2019

View full text Add to dashboard Cite

show abstract

“…A major limitation when investigating wound biofilm diagnostic and treatment methods is the availability of appropriate skin wound biofilm models . The porcine ex vivo wound model is most commonly used for investigating biofilm formation and assessing therapeutics .…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, there is an urgent need to investigate the monitoring and treatment of wound biofilms. A significant limiting factor is the availability of appropriate models of chronic wound biofilm infections using skin …”

mentioning

confidence: 99%

Electrical stimulation disrupts biofilms in a human wound model and reveals the potential for monitoring treatment response with volatile biomarkers

Ashrafi

Frazer

Morris

et al. 2018

Wound Repair Regeneration

View full text Add to dashboard Cite

Management of biofilm infections relies on time‐consuming laboratory techniques and monitoring treatment by subjective clinical evaluations. Due to these limitations, there is a need to explore alternative strategies. The aims of this study were to assess the feasibility of using volatile organic compound (VOC) biomarkers to monitor treatment response and measure anti‐biofilm efficacy of electrical stimulation (ES) in vitro and in human cutaneous wound biofilm models. Staphylococcus aureus (MSSA) and Pseudomonas aeruginosa (PA) biofilms were exposed to ES, ciprofloxacin, or both, with efficacy assessed and quantified by fluorescence staining, enumeration, metabolic assays, and biomass quantification; VOCs were measured by gas chromatography–mass spectrometry. In vitro MSSA and PA and ex vivo PA biofilms exposed to ES showed significantly reduced bacterial viability, metabolic activity, and biomass compared to controls (p < 0.05). There was significant variation in the relative abundance of VOCs in in vitro MSSA and PA and in ex vivo PA biofilms exposed to ES and antibiotic (p < 0.05). 2‐methyl‐1‐propanol was associated with MSSA viability (R = 0.93, p < 0.05), biomass (R = 0.97, p < 0.05), and metabolic activity (R = 0.93, p < 0.05) and 3‐methyl‐1‐butanol was associated with PA biomass (R = 0.93, p < 0.05). We showed that ES and VOC biomarkers are possible options for alternative nonpharmacological antimicrobial management of biofilms and noninvasive monitoring of wound infection treatment responses, respectively.

show abstract

“…Tight junction proteins are critical for the proper maintenance of skin barriers, and their malfunction may further promote biofilm formation [25][26][27][28][29].…”

Section: Discussionmentioning

confidence: 99%

“…related complications, such as peripheral neuropathy, cataract, retinopathy and/or obesity, may lead to poor maintenance of foot hygiene (i.e. less physical removal of biofilms and infected tissue), and dystrophic nails may lead to minor skin trauma followed by cracks [28][29][30].…”

Section: Discussionmentioning

confidence: 99%

Clinico-Mycological Study of Fungal Biofilms in Recalcitrant Onychomycosis

Mr¹,

Mh²,

Hm³

et al. 2017

Mycobact Dis

View full text Add to dashboard Cite

Objective: Studying the incidence of different predisposing factors of onychomycosis and the ability of fungal isolates to form biofilms. Background:Onychomycosis chronicity is referred to difficulties in eliminating the causative pathogens. Biofilms have become focus of era and considered to be one of the globally important causes of chronic recalcitrant infections. Fungi implicated in onychomycosis have the ability to form biofilms ''surface-attached multi-cellular communities''. Biofilm associated fungi acquire higher adaptive ability to overcome stressful conditions, higher antifungal resistance and evasion of host defensive systems. Moreover, they express community-based differential genes and more virulence activities.

show abstract

Chronic Wound Biofilm Model

Cited by 69 publications

References 54 publications

Phenazine Antibiotic‐Inspired Discovery of Bacterial Biofilm‐Eradicating Agents

Phenazine Antibiotic‐Inspired Discovery of Bacterial Biofilm‐Eradicating Agents

Electrical stimulation disrupts biofilms in a human wound model and reveals the potential for monitoring treatment response with volatile biomarkers

Clinico-Mycological Study of Fungal Biofilms in Recalcitrant Onychomycosis

Contact Info

Product

Resources

About